- Home
- ACIU vs FCCO Comparison
ACIU vs FCCO Comparison
Compare ACIU & FCCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- FCCO
- Stock Information
- Founded
- ACIU 2003
- FCCO 1994
- Country
- ACIU Switzerland
- FCCO United States
- Employees
- ACIU N/A
- FCCO N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- FCCO Major Banks
- Sector
- ACIU Health Care
- FCCO Finance
- Exchange
- ACIU Nasdaq
- FCCO Nasdaq
- Market Cap
- ACIU 247.4M
- FCCO N/A
- IPO Year
- ACIU 2016
- FCCO 1998
- Fundamental
- Price
- ACIU $1.98
- FCCO $22.36
- Analyst Decision
- ACIU Strong Buy
- FCCO Strong Buy
- Analyst Count
- ACIU 2
- FCCO 2
- Target Price
- ACIU $12.00
- FCCO $30.00
- AVG Volume (30 Days)
- ACIU 197.4K
- FCCO 42.8K
- Earning Date
- ACIU 03-13-2025
- FCCO 04-23-2025
- Dividend Yield
- ACIU N/A
- FCCO 2.69%
- EPS Growth
- ACIU N/A
- FCCO 16.77
- EPS
- ACIU N/A
- FCCO 1.81
- Revenue
- ACIU $30,136,397.00
- FCCO $65,129,999.00
- Revenue This Year
- ACIU $120.91
- FCCO $15.59
- Revenue Next Year
- ACIU $13.82
- FCCO $9.11
- P/E Ratio
- ACIU N/A
- FCCO $12.31
- Revenue Growth
- ACIU 84.51
- FCCO 12.17
- 52 Week Low
- ACIU $1.95
- FCCO $15.40
- 52 Week High
- ACIU $4.98
- FCCO $27.96
- Technical
- Relative Strength Index (RSI)
- ACIU 27.05
- FCCO 37.94
- Support Level
- ACIU $1.95
- FCCO $22.19
- Resistance Level
- ACIU $2.05
- FCCO $22.89
- Average True Range (ATR)
- ACIU 0.13
- FCCO 0.55
- MACD
- ACIU -0.02
- FCCO 0.11
- Stochastic Oscillator
- ACIU 6.38
- FCCO 60.45
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.